Earnings summaries and quarterly performance for AIM ImmunoTech.
Executive leadership at AIM ImmunoTech.
Board of directors at AIM ImmunoTech.
Research analysts who have asked questions during AIM ImmunoTech earnings calls.
Recent press releases and 8-K filings for AIM.
AIM ImmunoTech Reports Positive Interim Clinical Progress for Pancreatic Cancer Drug
AIM
New Projects/Investments
- AIM ImmunoTech Inc. reported positive year-end interim clinical progress from its Phase I/II DURIPANC study for Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) in metastatic pancreatic cancer patients.
- The study, which has enrolled 18 patients, demonstrated the combination therapy was safe and well-tolerated, with promising Progression-Free Survival and Overall Survival continuing from Phase I, and patients consistently reporting a high quality of life.
- Initial immune profiling showed a coordinated activation of innate and adaptive immune responses, suggesting an enhanced immune system by the combination.
- AIM holds a U.S. patent for Ampligen as an oncology treatment in combination with anti-PD-L1 therapies, providing protection until August 9, 2039, and has orphan drug designations in pancreatic cancer from both the U.S. and EU, offering market exclusivity post-commercial approval.
1 day ago
AIM ImmunoTech Inc. enters into Note Purchase Agreement
AIM
Debt Issuance
New Projects/Investments
- AIM ImmunoTech Inc. entered into an unsecured Promissory Note with Streeterville Capital, LLC on November 18, 2025, with an original principal amount of $3,301,250.00.
- The company received $2,500,000.00 from the transaction, after an original issue discount of $781,250.00 and a $20,000.00 transaction expense amount were deducted from the principal.
- The Note bears interest at 10% per annum compounded daily and matures 24 months from the Purchase Price Date.
- Mandatory prepayments are required for future fundraising, equal to the lesser of 12.5% of the amount raised or the outstanding balance.
- The investor has the right to redeem up to $250,000 per calendar month, starting six months after the Purchase Price Date.
Nov 19, 2025, 12:00 PM
Quarterly earnings call transcripts for AIM ImmunoTech.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more